



CURRICULUM VITAE

SIGNATURE:	<i>David J. Bodkin</i>	DATE:	2/26/2013
NAME:	David J. Bodkin, M.D.	DATE UPDATED:	February 2013
TITLE:	Investigator		

RESEARCH SITE ADDRESS & PHONE:

Main Office: TriWest Research Associates, LLC 300 South Pierce Street, Suite 201 El Cajon, CA 92020	Contact Info: Office: (619) 741-6895 Fax: (619) 589-6492 Email: info@trivestresearch.com
---	--

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE <i>(if applicable)</i>	YEAR(s)	FIELD OF STUDY
GCP Good Clinical Practice	Certificate	2012	Good Clinical Practice
NIH Protecting Human Research Participants	Certificate	2012	Protecting Human Research Participants
HIPAA	Training	2012	HIPAA

POSITIONS AND EMPLOYMENT:

2012-Present	Investigator, TriWest Research Associates, El Cajon, CA
2004-Present	Physician, Cancer Center Oncology Medical Group, San Diego, CA
1998-Present	Medical Director, Center for Cancer Treatment; Medical Director, Sharp Healthcare Oncology Services at Grossmont Hospital; and Medical Director, Hospice of Grossmont Hospital, La Mesa, CA
1996-1998	Associate Medical Director, Sharp HealthCare Oncology, La Mesa, CA
1995-Present	Sub-Investigator and Principal Investigator, Sharp HealthCare Oncology, La Mesa, CA
1993-1994	Attending Physician, Division of Hematology/Oncology, Veterans Affairs Medical Center, La Jolla, CA
1989-1994	Attending Physician, Division of Hematology/Oncology, Veterans Affairs Medical Center, La Jolla, CA
1989-1991	Clinical Instructor, Department of Medicine, University of California at San Diego, San Diego, CA
1991-Present	Clinical Assistant Professor, Department of Medicine, UCSD, San Diego, CA

RESEARCH TRIAL EXPERIENCE:

Phase II Study of A XXXX Antisense Gene Modified Allergenic Tumor Cell Vaccine in Patients with Non-Curable Non-small Cell Lung Cancer

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of XXXX on The Prevention of Chemotherapy-Induced Anemia and The Prevention of Chemotherapy-Induced Thrombocytopenia in Subjects with Non-Small Cell Lung Cancer Rec

A Phase III, Randomized, Double-Blind, Multicenter Study of the Efficacy of XXXX(Docetaxel) in Combination with Aptosyn (Exisulind) versus Taxotere (Docetaxel) with Placebo in Non-Small Cell Lung Cancer (NSCLC) Patients After Failure of Prior Platinum

Randomized, Double-Blind, Phase III comparative trial of 2 doses of XXXX in combination with gemcitabine and cisplatin versus placebo in combination with gemcitabine and cisplatin in chemotherapy-naïve patients with advanced (stage III or IV)

A Randomized, Phase II Trial of Three Combination Chemotherapy Regimens in Patients with Previously Untreated, Stage IIIB/IV, Non-Small Cell Lung Cancer: XXXX/XXXX/XXXX vs. Carboplatin/Irinotecan vs. Paclitaxel/Irinotecan

A Phase I, Randomized, Double-Blind, 2-Part, Multicenter Study to Compare the Efficacy of XXXX with the Efficacy of XXXX in Subjects with Locally Advanced or Metastatic (IIIB/IV) Non-Small Cell Lung Center after Failure of First-Line or 2nd

A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Effect of XXXX on the Prevention of Chemotherapy-Induced Anemia and the Prevention of Chemotherapy-Induced Thrombocytopenia in Subjects with NSCLC receiving Gemcitabine an

International, Randomized, Open-Label, Phase III Trial of Paclitaxel/Carboplatin Plus XXXX Versus Paclitaxel/Carboplatin Alone As First Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer

Randomized Study of XXXX, Carboplatin (PARAPLATIN), and Radiation Therapy for Locally Advanced, Inoperable Non-Small Cell Lung Cancer (NSCLC)

A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of XXXX in Combination with Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients with Non-Small Cell Lung Cancer

A Randomized Phase II Trial to Outline the Efficacy of Gemcitabine Containing Regimens (XXXX/XXXX or Gemzar/Cisplatin) When Used as Preoperative Chemotherapy in Patients with Stage I and II NSCLC

A Phase II Study of Temozolomide (SCH 52365) in the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer

A Randomized, Non-Comparative, Multicenter, Open-Label, Phase 2 Study of XXXX alone and of XXXX Plus Velcade (bortezomib) for Injection in Patients with Relapsed or Refractory, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Randomized, Double-Blind, Parallel, Three Arm, Multicenter, Phase II Trial Evaluating the Efficacy and Safety of XXXX in combination with Taxol®/Paraplatin® Alone in Previously U

A Randomized, Double-Blinded Phase II Study of Carboplatin/Paclitaxel/XXXX versus Carboplatin/Paclitaxel/Bevacizumab as First-Line Treatment for Recurrent or Advanced Non-Small Cell Lung Cancer with Non-Squamous Histology

A Randomized, Multicenter Phase II Study of XXXX/Carboplatin/Cetuximab Versus Taxane/Carboplatin as First-Line Treatment for Patients with Advanced/Metastatic NSCLC

A Randomized Multicenter Phase II Study of XXXX/Platinum/Cetuximab Versus Gemcitabine/Platinum as First-Line Treatment for Patients with Advanced Metastatic Non -Small Cell Lung Cancer.

Randomized Phase III Study of Docetaxel or Pemetrexed with or without Cetuximab in Patients with Recurrent or Progressive Non-Small Cell Lung Cancer after Platinum-Based Therapy

Phase II Study of First-Line Chemotherapy Using XXXX in Adult Patients with Non-Small Cell Lung Cancer who have PS=2

A Phase III, International, Randomized, Double-Blind, Parallel Group, Multicenter Study to Assess the Efficacy of XXXX Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Patients with Locally Advanced or Metastatic(Stage I)

A Multicenter, Non-Randomized, Phase II Evaluation of a Docetaxel, Bevacizumab and Tarceva Combination in Subjects with Locally Advanced or Metastatic Non-Squamous (Stage III or Stage IV) NSCLC (EGFR positive by FISH)

A Randomized, Phase II, Open Label Controlled Study of Two Different Doses and Schedules of XXXX in Combination with Premetrexed, or Premetrexed Alone, as Second-Line Treatment in Subjects with Stage IIIB/IV Non-Small Cell Lung Cancer and P

A Double-Blind, Randomized, Placebo-Controlled Phase III Study to Assess the Efficacy of XXXX –A3 + XXXX Antigen-specific Cancer Immunotherapy as adjuvant therapy in patients with resectable MAGE- A3-positive Non Small Cell Lung Cancer

The impact of Ethnic Origin on Patients being Treated Second-Line with Pemetrexed- An Observational Study

An Open Label Randomized Phase II/III Study Comparing Two Combination Modalities of IV XXXX and IV Doctaxel (taxotere) with IV Docetaxel (Taxotere) Alone in Patients with Non-Small Cell Cancer Previously treated with Platinum-based Che

Randomized Phase III Trial Comparing Targretin capsules Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel in Chemotherapy-naïve patients with Advanced or Metastatic Non-Small Cell Lung Cancer

Multi-center, Randomized, Open Label Study to Evaluate the Safety and Efficacy of Combined Immunotherapy with Subcutaneous XXXX, and Histamine Dihydrochloride Versus Subcutaneous Interleukin-2 Alone in Patients with Advanced Malignant Melanoma

A Randomized, Open-Label, Phase 3 Trial of XXXX in Combination with Paclitaxel and Carboplatin vs. Paclitaxel and Carboplatin Alone for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

- A Randomized Phase II Study of Single Agent XXXX VS Standard Chemotherapy in Patients with Previously Untreated Advanced NSCLC and a Poor Performance Status
- A Randomized, Phase IIB, Multi-center Study of XXXX versus Erlotinib in Patients with Stage IIIB/IV Non Small Cell Lung Cancer After Failure of at Least 1 Prior Platinum-Based Treatment
- A Randomized, Double-Blind, Placebo-Controlled, Phase III Study of XXXX or Placebo Added to Whole Brain Radiation Therapy for the Treatment of Brain Metastases from Non-Small Cell Lung Cancer
- A Randomized Phase II, Multi-Center, Open-Label Trial of XXXX and Docetaxel in Patients with Advanced Non Small Cell Lung Cancer
- A Randomized, Phase II/III Multi-Center Trial of XXXX Plus Cisplatin and Docetaxel Plus 5-Fluorouracil (5-FU) Versus Cisplatin Plus 5-Fluorouracil in the First-Line Treatment of Patients with Recurrent and/or Metastatic Squamous Cell Car
- A Multi-Center, Randomized, Phase III Study of XXXX plus Cisplatin vs Docetaxel plus Carboplatin vs Navelbine plus Cisplatin in Chemotherapy-naïve patients with advanced (Stage IIIB) and recurrent or metastatic (Stage IV) Non-Small Cell Lung Cancer
- An Open-Label, Multi-Center, Randomized, Phase III Study Comparing XXXX/XXXXcs. Etoposide/Cisplatin as First-Line for Patients with Extensive Disease Small Cell Lung Cancer
- An Open-Label, Multi-Center, Randomized, Phase II Comparator Study of Oral XXXX versus Intravenous Topotecan for Second-Line Therapy in Patients with SCLC who have Relapsed Greater than or Equal to 90 days after Completion of First-Line Therapy
- An Open-Label, Multi-Center, Randomized, Phase III Study Comparing Oral XXXX/XXXX versus Etoposide/Cisplatin as Treatment for Chemotherapy-Naïve Patients with Extensive Disease-Small Cell Lung Cancer
- A Phase 2 Exploratory Study of XXXX and XXXX in Patients with Non-Small Cell Lung Carcinoma Who Are Progressing on Erlotinib Protocol
- A Phase II Study of XXXX with or without 5-Fluorouracil as Second Line Therapy of Advanced Esophageal or Gastric Adenocarcinoma
- A Phase III Randomized Study of XXXX VS Gefitinib (Iressa) as Third Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- A Phase II Open, Multi-Center Trial to Assess the Activity and Tolerability of XXXX Given Intravenously as Second-Line Therapy to patients with Small Cell Lung Cancer Who Have Failed One Prior Platinum Based Chemotherapy Regimen